Can losartan reduce fibrosis and slow the decline of kidney function in kidney transplant patients?

The effect of the renin-angiotensin system inhibitors after renal transplantation on chronic allograft nephropathy through down regulation of TGF ß and miR 21 in kidney transplant patients Labbafinejad center of Tehran

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN15884223

Enrollment

Registered

2016-06-25

Start date

2013-11-19

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allograft nephritis Urological and Genital Diseases Allograft nephritis

Interventions

Participants are randomly allocated to one of two groups. Intervention group: Participants receive 25mg oral losartan daily for six months post transplantation. Control group: Participants receive no

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. First kidney transplantation of living unrelated donor 2. Compliance to losartan 3. No allergic reaction to losartan 4. Agreement to participate in the study

Exclusion criteria

Exclusion criteria: 1. Second transplant 2. Cadaveric transplant 3. Acute rejection during first week after transplantation 4. Delayed graft function during first week after transplantation

Design outcomes

Primary

Measure	Time frame
1. Graft function is determined by measuring eGFR at 48 hours, 3 and 6 months post transplantation 2. Fibrosis is measured by measuring TGF-ß and miR 21 levels using real time PCR at 48 hours, 3 and 6 months post transplantation	—

Secondary

Measure	Time frame
No secondary outcome measures.	—

Countries

Iran

Contacts

Public ContactBehrang Alipour

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026